Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1989 Sep;77(3):410–416.

Interleukin-2 can induce suppression of human natural killer cell cytotoxicity.

K Hellstrand 1, S Hermodsson 1
PMCID: PMC1542047  PMID: 2509116

Abstract

By interaction with monocytes, interleukin-2 (IL-2) suppressed natural killer (NK) cell cytotoxicity (NKCC) of human, Percoll-fractionated, low-density mononuclear cells. The NK-suppressive effect of IL-2 was independent of de novo formation of prostaglandins or protein since it was unaffected by treatment with indomethacin and cycloheximide, respectively. A monoclonal antibody to the p55 (beta) moiety of the IL-2 receptor (anti-Tac/anti-CD25) blocked IL-2-induced NKCC suppression but did not affect the NK-enhancing effect of the lymphokine. We conclude that IL-2 exerts a monocyte-dependent, IL-2 beta-receptor mediated suppressive influence on human NK cells.

Full text

PDF
410

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloom E. T., Babbitt J. T., Kawakami K. Monocyte-mediated augmentation of human natural killer cell activity: conditions, monocyte and effector cell characteristics. J Immunol. 1986 Jul 1;137(1):172–178. [PubMed] [Google Scholar]
  2. Brooks C. G., Henney C. S. Interleukin-2 and the regulation of natural killer activity in cultured cell populations. Contemp Top Mol Immunol. 1985;10:63–92. doi: 10.1007/978-1-4684-4838-2_3. [DOI] [PubMed] [Google Scholar]
  3. Dempsey R. A., Dinarello C. A., Mier J. W., Rosenwasser L. J., Allegretta M., Brown T. E., Parkinson D. R. The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol. 1982 Dec;129(6):2504–2510. [PubMed] [Google Scholar]
  4. Domzig W., Stadler B. M., Herberman R. B. Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol. 1983 Apr;130(4):1970–1973. [PubMed] [Google Scholar]
  5. Falkoff R. M., Peters M., Fauci A. S. T cell enrichment and depletion of human peripheral blood mononuclear cell preparations. Unexpected findings in the study of the functional activities of the separated populations. J Immunol Methods. 1982;50(1):39–49. doi: 10.1016/0022-1759(82)90302-7. [DOI] [PubMed] [Google Scholar]
  6. Goto T., Herberman R. B., Maluish A., Strong D. M. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol. 1983 Mar;130(3):1350–1355. [PubMed] [Google Scholar]
  7. Hanna N. The role of natural killer cells in the control of tumor growth and metastasis. Biochim Biophys Acta. 1985;780(3):213–226. doi: 10.1016/0304-419x(85)90004-6. [DOI] [PubMed] [Google Scholar]
  8. Hellstrand K., Hermodsson S. Differential effects of histamine receptor antagonists on human natural killer cell activity. Int Arch Allergy Appl Immunol. 1987;84(3):247–255. doi: 10.1159/000234431. [DOI] [PubMed] [Google Scholar]
  9. Hellstrand K., Hermodsson S. Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol. 1986 Jul 15;137(2):656–660. [PubMed] [Google Scholar]
  10. Hellstrand K., Hermodsson S. Role of serotonin in the regulation of human natural killer cell cytotoxicity. J Immunol. 1987 Aug 1;139(3):869–875. [PubMed] [Google Scholar]
  11. Holter W., Goldman C. K., Casabo L., Nelson D. L., Greene W. C., Waldmann T. A. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol. 1987 May 1;138(9):2917–2922. [PubMed] [Google Scholar]
  12. Jeansson S., Brorson J. E. Elimination of mycoplasmas from cell cultures utilizing hyperimmune sera. Exp Cell Res. 1985 Nov;161(1):181–188. doi: 10.1016/0014-4827(85)90502-6. [DOI] [PubMed] [Google Scholar]
  13. Kabelitz D., Kirchner H., Armerding D., Wagner H. Recombinant interleukin 2 rapidly augments human natural killer cell activity. Cell Immunol. 1985 Jun;93(1):38–45. doi: 10.1016/0008-8749(85)90386-7. [DOI] [PubMed] [Google Scholar]
  14. Kang Y. H., Carl M., Watson L. P., Yaffe L. Immunoultrastructural studies of human NK cells: II. Effector-target cell binding and phagocytosis. Anat Rec. 1987 Mar;217(3):290–304. doi: 10.1002/ar.1092170309. [DOI] [PubMed] [Google Scholar]
  15. Kehrl J. H., Dukovich M., Whalen G., Katz P., Fauci A. S., Greene W. C. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. J Clin Invest. 1988 Jan;81(1):200–205. doi: 10.1172/JCI113295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Koren H. S., Anderson S. J., Fischer D. G., Copeland C. S., Jensen P. J. Regulation of human natural killing. I. The role of monocytes, interferon, and prostaglandins. J Immunol. 1981 Nov;127(5):2007–2013. [PubMed] [Google Scholar]
  17. Lotze M. T., Frana L. W., Sharrow S. O., Robb R. J., Rosenberg S. A. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985 Jan;134(1):157–166. [PubMed] [Google Scholar]
  18. Mazumder A., Rosenberg S. A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984 Feb 1;159(2):495–507. doi: 10.1084/jem.159.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mulé J. J., Ettinghausen S. E., Spiess P. J., Shu S., Rosenberg S. A. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res. 1986 Feb;46(2):676–683. [PubMed] [Google Scholar]
  20. Mulé J. J., Shu S., Rosenberg S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol. 1985 Jul;135(1):646–652. [PubMed] [Google Scholar]
  21. Ortaldo J. R., Mason A. T., Gerard J. P., Henderson L. E., Farrar W., Hopkins R. F., 3rd, Herberman R. B., Rabin H. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol. 1984 Aug;133(2):779–783. [PubMed] [Google Scholar]
  22. Remick D. G., Larrick J. W., Nguyen D. T., Kunkel S. L. Stimulation of prostaglandin E2 and thromboxane B2 production by human monocytes in response to interleukin-2. Biochem Biophys Res Commun. 1987 Aug 31;147(1):86–93. doi: 10.1016/s0006-291x(87)80090-6. [DOI] [PubMed] [Google Scholar]
  23. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  24. Rosenberg S. A. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg. 1988 Aug;208(2):121–135. doi: 10.1097/00000658-198808000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Siegel J. P., Sharon M., Smith P. L., Leonard W. J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science. 1987 Oct 2;238(4823):75–78. doi: 10.1126/science.3116668. [DOI] [PubMed] [Google Scholar]
  26. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  27. Timonen T., Saksela E. Isolation of human NK cells by density gradient centrifugation. J Immunol Methods. 1980;36(3-4):285–291. doi: 10.1016/0022-1759(80)90133-7. [DOI] [PubMed] [Google Scholar]
  28. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES